14 Analysts Assess Regeneron Pharmaceuticals: What You Need To Know
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 14 Wall Street analysts have published their opinions on Regeneron Pharmaceuticals (NASDAQ:REGN), with an average 12-month price target of $920.0, a high of $1045.00, and a low of $800.00. The current average price target has increased by 4.74% from the previous average of $878.38. Analysts' ratings range from 'Buy' to 'Hold', with various actions taken including maintaining, raising, and lowering price targets. Regeneron is involved in developing treatments for various diseases and has several marketed products. Financially, the company shows strong performance with a high net margin and ROE, low debt-to-equity ratio, but a revenue growth rate lower than the Health Care sector average.
December 18, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron Pharmaceuticals has received a mix of bullish and neutral ratings from analysts, with an updated average price target of $920, indicating a positive sentiment among analysts.
The increase in the average price target and the predominance of 'Buy' and 'Outperform' ratings suggest a positive short-term impact on REGN's stock price. The strong financial indicators such as high net margin and ROE, coupled with a low debt-to-equity ratio, support this outlook. However, the slower revenue growth compared to the sector average tempers the potential upside, hence the importance is not at the maximum.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100